Oral SCA administration to APP/PS1 transgenic mice significantly improved spatial learning and memory and suppressed pro-inflammatory cytokines, and was associated with cognitive and neuropathological improvements alongside alterations in gut microbiota and hippocampal metabolism.
Abstract
Sciadonic acid (SCA) is a fatty acid derived from Torreya grandis oil with known anti-inflammatory and antioxidant properties; however, its role in Alzheimer's disease (AD) remains undefined. In this study, oral SCA administration to APP/PS1 transgenic mice significantly improved spatial learning and memory, as assessed by Morris water maze and Y-maze tests. Histological examination revealed reduced neuronal loss, preserved neuropil architecture, and diminished Aβ plaque burden in the hippocampus and cerebral cortex. SCA treatment enhanced antioxidant capacity, as indicated by elevated superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities, alongside decreased malondialdehyde (MDA) and nitric oxide (NO) levels. Furthermore, SCA restored colonic mucosal integrity and suppressed pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). Gut microbiota analysis revealed reversal of dysbiosis, with an increased Bacillota/Bacteroidetes ratio, enrichment of beneficial taxa such as Lactobacillus, and elevated short-chain fatty acid (SCFA) levels. Non-targeted hippocampal metabolomics identified modulation of 16 metabolites, predominantly in taurine and hypotaurine, and pyrimidine pathways. Collectively, SCA administration was associated with cognitive and neuropathological improvements alongside alterations in gut microbiota and hippocampal metabolism.
Long-term metformin pretreatment attenuated STZ-induced AD-like pathology and cognitive deficits and its neuroprotective effects were associated with increased hippocampal Klotho expression and reduced oxidative stress and neuro inflammation, supporting further investigation of metformin and the Klotho pathway as poten...
Farzane Shanehbandpour-Tabari, Ravieh Golchoobian, F. Pourabdolhossein· European Journal of Pharmaco...· 0 citations
Alzheimer's disease (AD), a progressive neurodegenerative disorder, characterized by the deposition of amyloid-β plaques in the hippocampus, leading to cognitive and behavioral impairments. This study investigated the neuroprotective outcome of Dapagliflozin (DAPA), a sodium-glucose cotransporter 2 inhibitor primarily...
Lovekesh Singh, Ghanshyam Das Gupta, Shamsher Singh· Assay and drug development t...· 0 citations
Findings demonstrate that APS alleviates cognitive deficits and AD-like pathology, partially through remodeling gut microbiota and modulating the gut-brain axis, and represents a promising natural compound-based therapeutic candidate for managing cognitive decline associated with Alzheimer’s disease.
Xiaolin Cui, Zhen Wei, Qingshui Wang et al.· Frontiers in Pharmacology· 0 citations
Investigation of the neuroprotective potential and associated signaling alterations of erinacine C using APP/PS1 transgenic mice and Aβ25-35-induced PC12 cells suggest that EC may mitigate cognitive impairment and neurodegeneration in parallel with alterations in the Akt/GSK3β/tau/caspase-3 signaling response.
Objective Maternal immune activation (MIA) is a key risk factor for schizophrenia-related cognitive deficits, linked to prefrontal cholinergic dysfunction. Nauclea officinalis extract (NOE) possesses documented anti-inflammatory and neuroprotective properties, but its effects on MIA-induced cognitive and neuronal dysfu...
L. An, Zhan-Yong Li, Yan Wang et al.· Frontiers in Cell and Develo...· 0 citations
Whether long-term HSD exacerbates cognitive and emotional deficits in APP/PS1 transgenic mice is investigated and the underlying gut–brain axis mechanisms involving microbiota dysbiosis, peripheral and central inflammation, hippocampal neuronal integrity, and metabolic alterations are explored.
Huan-Min Zhang, Jin-Xin Kou, Peng-Fei Ge et al.· Frontiers in Microbiology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.